Milnocor (Milrinone)

Milrinone blocks the enzyme phosphodiesterase‑3, leading to higher intracellular cyclic AMP levels in heart muscle and vascular smooth muscle. This raises calcium availability for stronger heart contractions and relaxes blood vessels, producing both inotropic and vasodilatory effects.

The dosing regimen for milrinone is individualized by the treating physician based on the patient’s clinical status, weight, renal function, and response. Only a qualified prescriber should determine the infusion rate and duration.

Safety data for milrinone in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the Milnocor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Milnocor (milrinone) differs from catecholamine inotropes such as dobutamine by acting via phosphodiesterase‑3 inhibition rather than beta‑adrenergic stimulation. This results in combined inotropic and vasodilatory effects, which can be advantageous in patients with high systemic vascular resistance, but it may also increase the risk of hypotension.

Milnocor should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture and direct light. Do not freeze. Follow standard aseptic handling procedures for intravenous solutions.

Milnocor is given as an intravenous infusion. The initial loading dose is typically administered over a short period, followed by a continuous maintenance infusion. Administration must be performed in a setting where cardiac monitoring and emergency support are available.

The most serious adverse events include severe ventricular arrhythmias, myocardial ischemia, and profound hypotension. Continuous ECG and hemodynamic monitoring are essential to detect and manage these risks promptly.

Milnocor is contraindicated in patients with known hypersensitivity to milrinone or any component of the formulation, and in those with severe aortic or mitral valve stenosis where increased contractility could worsen obstruction. Caution is also advised in patients with uncontrolled arrhythmias.